Adverse Events in Targeted Radionuclide Therapy

Area of Science:

• Oncology
• Nuclear Medicine
• Radiopharmaceutical Therapy

Background:

• Targeted radionuclide therapy (TRT) is a cornerstone in managing specific cancers, including thyroid, prostate, and neuroendocrine tumors.
• The utilization and indications for TRT have seen significant expansion, supported by ongoing clinical trials.

Purpose of the Study:

• To provide a comprehensive review of adverse events associated with targeted radionuclide therapy.
• To detail the clinical manifestations, incidence, risk factors, and management strategies for TRT-related adverse events.
• To outline preventive measures for minimizing the risk of adverse events in patients undergoing TRT.

Main Methods:

• Systematic review of literature on adverse events in targeted radionuclide therapy.
• Analysis of clinical manifestations, incidence rates, and identified risk factors.
• Evaluation of current management and prevention strategies for TRT-induced toxicities.

Main Results:

• TRT is associated with a spectrum of potential adverse events that require careful monitoring.
• Risk factors and specific clinical presentations vary depending on the TRT agent and target.
• Effective management and preventive strategies are crucial for optimizing patient outcomes.

Conclusions:

• Physicians must possess adequate knowledge of TRT adverse events for optimal patient care.
• Proactive management and risk mitigation are essential for the safe and effective application of TRT.
• The expanding role of TRT necessitates continued research into its safety profile and management.